Anthem Biosciences Ltd

Stage 3 · Topping · week 2

As of 20 Nov 2026, Anthem Biosciences is in Stage 3, the topping phase, now in week 2 (since 11 Nov 2026). It closed at ₹951, 0.7% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. More about the company

₹951.1
Close, 20 Nov 2026
+1.52% on the day
₹53,594 Cr · Large cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dBiotechnology 33.3%0.0 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

ANTHEM's uptrend is tiring: 2 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 86 of 99, a leader among NSE stocks over the past year. Biotechnology ranks 11 of 106 industries by the strength of its stocks, among the leaders.

Is ANTHEM early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2025-07-21 → 2026-11-20
S? 42w
S2 25w
2025-07-212026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S1 1w → S2 25w → S3 1w current
Total tracked: 70 weeks across 4 stage runs.

ANTHEM among Biotechnology3rd of 9 by relative strength

All 9 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1ACUTAASStage 2 · wk 396+21.6%
2SAILIFEStage 2 · wk 3796+29.2%
3ANTHEMStage 3 · wk 286+18.1%
4HESTERBIOStage 3 · wk 786+7.4%
53BBLACKBIOStage 2 · wk 761−1.0%
6ONESOURCEStage 1 · wk 158+18.6%
7BIOCONStage 4 · wk 550+8.8%
8PANACEABIOStage 4 · wk 845−1.0%
vs 52W High
-0.7%
₹587.9 lo₹958.2 hi
Near 52W high, distribution zone
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 2
1w13w26w
Week 2, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
20.7%
200 DMA: ₹787.9 · rising
The stock still holds above its 200-day average, but the trend has flattened. A close below the line would add to the Stage 4 risk.
Rel Volume
0.55x
vs 50-day avg
Volume was well below average. Quiet sessions say little in a topping stock. Volume on the down days matters more.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+18.1%
3M
+7.8%
6M
+21.9%
YTD
+46.0%
1Y
+36.2%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Biotechnology
→ Flat
Stage 2%
33.3%
20d Δ
+0.0pp
1M return
+17.1%
3M return
+4.9%
Industry Stage-2 % · last 20 days
Industry has 3 Stage 2 leaders. See Biotechnology Stage 2 →

Mutual fund holdings

Held by 75 mutual funds in portfolios to October 2026: 29 active funds and 46 index funds and ETFs.

In October, among active funds: 7 increased, 1 opened a new position and 5 exited.

8 increased or opened5 reduced or exited
All 75 funds, the 5 that exited, and what each did in October

Mutual funds holding ANTHEM: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 20 May 2026
Recent Stage Timeline
2026-11-20S3
Wk 2 · Vol 0.55x
2026-11-19S3
Wk 2 · Vol 0.75x
2026-11-18S3
Wk 2 · Vol 0.48x
2026-11-17S3
Wk 1 · Vol 0.52x
2026-11-16S3
Wk 1 · Vol 0.43x
2026-11-13S3
Wk 1 · Vol 0.49x
2026-11-12S3
Wk 1 · Vol 0.53x
2026-11-11S32→3
Wk 1 · Vol 0.66x
2026-11-09S2
Wk 24 · Vol 2.50x
2026-11-06S2
Wk 24 · Vol 0.73x
2026-11-05S2
Wk 24 · Vol 0.98x
2026-11-04S2
Wk 24 · Vol 1.47x
Moving averages & range
50 DMA
₹884.8
200 DMA
₹787.9
52W High
₹958.2
52W Low
₹587.9
5D Low
₹914.4
Resistance levels (recent highs)
20d High
₹958.2
60d High
₹958.2
120d High
₹958.2
250d High
₹958.2
Next resistance
+0.7%
to 20d High
P/E (TTM)
87.9
Forward 59.5
Earnings Growth (YoY)
+21.6%
Revenue +8.0%
ROE
+20.4%
Profit margin +29.9%
Dividend Yield
0.21%
P/B 16.3

Anthem Biosciences: quick answers

What stage is Anthem Biosciences in?

As of 20 Nov 2026, Anthem Biosciences (ANTHEM) is in Stage 3, the topping phase. It entered Stage 3 on 11 Nov 2026 and is in week 2. What the four stages mean

Is Anthem Biosciences in an uptrend?

Its uptrend has stalled. Anthem Biosciences is in Stage 3, the topping phase that follows an advance. It trades 20.7% above its 200-day average, which is rising.

How far is Anthem Biosciences from its 52-week high?

Anthem Biosciences closed at ₹951 on 20 Nov 2026, 0.7% below its 52-week high of ₹958. Its 52-week low is ₹588.

How has Anthem Biosciences performed over the past year?

As of 20 Nov 2026, Anthem Biosciences is up 36.2% over the past year and up 46.0% so far in 2026.

Which sector and industry is Anthem Biosciences in?

Anthem Biosciences is in the Biotechnology industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care

About this companyHealth Care· Biotechnology

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.